Erlotinib in EGFR TKI-progressed lung cancer: Retrospective real-world insights from a tertiary cancer center in South India

Background: Osimertinib benefits patients with non-small cell lung cancer (NSCLC), progressing on first-line epidermal growth factor receptor (EGFR) tyrosine-kinase-inhibitors (TKIs), but high cost restricts access in low- and middle-income countries (LMICs). We evaluated erlotinib rechallenge in th...

Descripción completa

Detalles Bibliográficos

Autores principales:	Pragadeesh Thamaraiselvan, Arvind Krishnamurthy, Alexander John, Vijayalakshmi Ramshankar, Shirley Sundersingh, Venkatraman Radhakrishnan
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wolters Kluwer Medknow Publications 2026-01-01
Colección:	Cancer Research, Statistics, and Treatment
Materias:	egfr mutated erlotinib non-small cell lung carcinoma targeted therapy tki progression
Acceso en línea:	https://journals.lww.com/crst/fulltext/2026/01000/erlotinib_in_egfr_tki_progressed_lung_cancer_.4.aspx
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!